FDA accelerates review of Shire product

Wednesday 24 February 2010

The US Food and Drug Administration has accelerated its review of a new product for Fabry disease produced by Shire Plc as supply shortages of the only currently marketed treatment for the disease continue.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom